REPL - Replimune climbs on promising Phase 2 data for skin cancer therapy

Replimune Group (REPL) is trading ~7.6% higher in early hours after announcing favorable interim results from a Phase 2 study for the combination RP1 (vusolimogene oderparepvec) with Opdivo (nivolumab) in a cohort of patients with skin cancer.In the CERPASS study, at the current data cut-off (n=15), seven out of nine responses are complete responses with a current CR rate of 46% and overall response rate ((ORR)) of 60%, the company said adding that a potentially eighth complete response requires biopsy confirmation.CERPASS study is a randomized, global Phase 2 clinical study targeting to enroll 180 patients with locally advanced or metastatic cutaneous squamous cell carcinoma ((CSCC)) who have not responded to anti-PD1 therapy. The initial readout is expected in 2022.The data indicate that RP1 in combination with Opdivo leads to “deep and durable responses in patients with CSCC with the number of complete responses ((CRs)), a dual independent primary endpoint in the CERPASS study, continuing

For further details see:

Replimune climbs on promising Phase 2 data for skin cancer therapy